Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia AreataRelease Date:Education Inflammation & Immunology USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi ArabiaRelease Date:Research Vaccines Saudi Arabia Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing EquityRelease Date:Education Inflammation & Immunology Australia Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality ImprovementRelease Date:Quality Improvement Oncology Kazakhstan Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer CareEducation Oncology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative StrategiesRelease Date:Quality Improvement Oncology All Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology PracticeRelease Date:Education Oncology USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology China, France, Germany, Italy, Japan, Spain, Turkey, United Kingdom Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding DisordersRelease Date:Research Rare Disease All Biochemical and Molecular Characterization of Marstacimab and TFPI PathwaysRelease Date:Research Rare Disease Brazil, China, Germany, Italy, Japan, Korea, Netherlands, Saudi Arabia, Spain, Turkey, USA, United Kingdom Optimizing RSV diagnosis by improving RSV detection in patients admitted to ED/hospitalized due to respiratory symptomsRelease Date:Quality Improvement Vaccines Austria, Belgium, Bulgaria, Czech Republic, Finland, Greece, Ireland, Israel, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Sweden, Switzerland Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence ApproachRelease Date:Research Inflammation & Immunology USA Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUCEducation Oncology USA Advancing Genomic Competence and Patient Centered Care in Metastatic Breast CancerRelease Date:Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction ManagementRelease Date:Research Internal Medicine Australia, Canada, China, Germany, Greece, Japan, Korea, Taiwan Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-positRelease Date:Education Oncology United States Minor Outlying I OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic MalignanciesRelease Date:Quality Improvement Oncology China Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory OutcomeRelease Date:Education Vaccines USA Title Grant Type Focus Area Country Application Due Date Prostate Cancer: Best Practices for Combining Targeted Therapies in mPCRelease Date:Education Oncology USA Transthyretin Cardiac Amyloidosis FellowshipRelease Date:Research Rare Disease USA Optimizing Adult Vaccination Ecosystem in IndiaRelease Date:Quality Improvement Vaccines India Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology Spain Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Populations in TurkeyRelease Date:Research Vaccines Turkey